World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
50030
World Ranking
14815
National Ranking
476

Overview

Alain Ravaud is affiliated with the University of Bordeaux in France and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research spans multiple subfields, with significant focus on pulmonary and respiratory medicine, oncology, surgery, molecular biology, and cancer research.

Their work has concentrated primarily on topics such as renal cell carcinoma treatment, cancer immunotherapy and biomarkers, bladder and urothelial cancer treatments, renal and related cancers, cancer genomics and diagnostics, urinary and genital oncology studies, and pancreatic and hepatic oncology research.

Frequent publication venues for Ravaud's research include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • European Urology
  • Cancers
  • Journal for ImmunoTherapy of Cancer

Among recent papers authored in collaboration with other researchers, notable titles include:

  • Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial, 2020, Journal for ImmunoTherapy of Cancer
  • Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma, 2020, Clinical Cancer Research
  • The official French guidelines to protect patients with cancer against SARS-CoV-2 infection, 2020, The Lancet Oncology
  • Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder, 2022, European Urology

Ravaud frequently collaborates with several researchers who have co-authored multiple publications with them. These include Marine Gross-Goupil, Jean-Christophe Bernhard, Charlotte Domblides, Amaury Daste, and Bernard Escudier.

Best Publications

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

    Bernard Escudier;Anna Pluzanska;Piotr Koralewski;Alain Ravaud

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

    Sylvie Negrier;Bernard Escudier;Christine Lasset;Jean-Yves Douillard

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

    Bernard Escudier;Joaquim Bellmunt;Sylvie Négrier;Emilio Bajetta

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Gwenaelle Gravis;Karim Fizazi;Florence Joly;Stéphane Oudard

  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

    Alain Ravaud;Robert J. Motzer;Hardev S. Pandha;Daniel J. George

  • Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

    L Capuron;A Ravaud;P J Neveu;A H Miller

  • Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

    Andrea B. Apolo;Jeffrey R. Infante;Ani Balmanoukian;Manish R. Patel

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

    Toni K. Choueiri;Anne Plantade;Paul Elson;Sylvie Negrier

  • Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

    Thomas Powles;Mark Kockx;Alejo Rodriguez-Vida;Ignacio Duran

  • Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer

    Pierre Soubeyran;Marianne Fonck;Christèle Blanc-Bisson;Jean-Frédéric Blanc

  • Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie

    S. Négrier;B. Escudier;F. Gomez;J.-Y. Douillard

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou
Christine Chevreau
Christine Chevreau DuPont (United States)
Thomas Powles
Thomas Powles Queen Mary University of London
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Daniel J. George
Daniel J. George Duke University
Toni K. Choueiri
Toni K. Choueiri Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a medical career in the USA, explore alternative pathways and flexible online degree options. For those already working as nurses, pursuing an rn to bsn online no clinicals program can be a practical way to advance your credentials without the need for additional clinical rotations.

Ambitious nurses who wish to lead in healthcare often choose doctoral-level degrees. Finding the fastest dnp program or the cheapest online dnp programs can help students save time and reduce debt while still achieving top qualifications. These programs are increasingly offering online options, making it easier to balance work, life, and education.

If your goal is to enter the healthcare workforce quickly, you might consider what is the fastest way to become an lpn. Fast-track online LPN programs can help you start your nursing career in as little as one year.

In summary, online medical and nursing degrees offer flexible, accelerated, and affordable routes to a rewarding healthcare career.

Best Scientists Citing Alain Ravaud

Trending Scientists

Recently Published Articles